We found that intestinal tumor ILC2s had increased expression of IL-25R, but did not express ST2, and while the pro-tumoral effects of IL-25 required ILC2s, IL-33 acted independently of ILC2s correlating instead with mast cell and Treg expansion. The gene discussed is IL33; the disease is intestinal neoplasm.